Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Sangamo Therapeutics, Inc.

Sangamo Therapeutics, Inc. (SGMO) Stock Overview

Explore Sangamo Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

SGMO●PNK
HealthcareBiotechnology
$0.07
$0.00(0.00%)
U.S. Market opens in 19h 40m

Sangamo Therapeutics, Inc. (SGMO)

Meyka AI Score

Z

Key Financials

Market Cap30.7M
P/E Ratio-0.20
EPS (TTM)$-0.37
ROE66.86%
Fundamental Analysis

AI Price Forecasts

1 Month$0.08
3 Months$0.06
1 Year Target$0.29

SGMO Stock Analysis & Investment Overview (PNK)

Our AI-powered analysis of Sangamo Therapeutics, Inc. (PNK: SGMO) gives investors deep insight into how the stock performs on the PNK exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Sangamo Therapeutics, Inc.'s PNK-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of SGMO on the PNK shows an RSI of 28.15, suggesting the stock is in a an oversold condition. Our forecasting models predict a 12-month price target of $0.29 for the PNK listing.

Key metrics behind Sangamo Therapeutics, Inc.'s PNK-traded stock include a P/E ratio of -0.20 and a market capitalization of 30.7M. Combined with our AI analysis, these give both institutional and retail investors a clear view of SGMO on the PNK.

Price Performance (PNK: SGMO)

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
N/A
3-Month Change
-61.07%
6-Month Change
-80.50%
Year-to-Date (YTD) Change
-82.38%
1-Year Change
-87.62%
3-Year Change
-94.39%
5-Year Change
-99.23%
All-Time (Max) Change
-99.51%

Contact Information

https://www.sangamo.com
510 970 6000
501 Canal Blvd, Richmond, CA, 94804

Company Facts

1,270 Employees
IPO DateApr 6, 2000
CountryUS

Frequently Asked Questions